Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31544929 | 0.88 | ESR1 (0.58) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL11503300 | 0.84 | OPRM1 (0.49) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL19017738 | 0.80 | FOLH1 (0.45) | LMNAADRA1ACYP3A4CYP2C9ADRB2 | |
| SCHEMBL9918287 | 0.79 | OPRM1 (0.66) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL9918290 | 0.79 | OPRM1 (0.66) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL4634694 | 0.77 | ESR1 (0.78) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL21138174 | 0.77 | ADRB2 (0.39) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL69138 | 0.76 | ALOX15 (0.48) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL19688904 | 0.75 | HKDC1 (0.41) | LMNAADRA1AOPRM1CYP3A4CYP2C9 | |
| SCHEMBL11830368 | 0.75 | ADRB2 (0.51) | LMNAADRA1AOPRM1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-7759526-B2 | Pharmaceutical compositions comprising cannabidiol derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2010-07-20 | — | — | US | disclosed |
| EP-1289517-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL DERIVATIVES | YISSUM RES DEV CO (IL) | 2005-11-16 | — | — | EP | disclosed |
| US-20030166727-A1 | Pharmaceutical compositions comprising cannabidiol derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-09-04 | — | — | US | disclosed |
| US-4876276-A | ANALGESICS, ANTIEMETICS, AND ANTIGLAUCOMA AGENTS NO CANNABIMIMETIC EFFECTS | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-10-24 | — | — | US | disclosed |
| US-4179517-A | DEVOID OF \"CANNABIS-TYPE\" CENTRAL NERVOUS SYSTEM ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166727-A1 | Pharmaceutical compositions comprising cannabidiol derivatives | CNR2, CNR1, FAAH | LMNA 2253/4885ADRA1A 1078/4885OPRM1 18/4885 |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | F12, PHAX, WDR82 | LMNA 2207/4885ADRA1A 351/4885OPRM1 692/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | LMNA 1921/4885ADRA1A 4459/4885OPRM1 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.